Yoshio Miki

List of Publications by Year
in descending order

45 papers	2,759 citations	218381 26 h-index	264894 42 g-index
49 all docs	49 docs citations	49 times ranked	4519 citing authors

#	Article	IF	Citations
1	BRCA2 represses the transcriptional activity of pS2 by E2-ERÎ±. Biochemical and Biophysical Research Communications, 2022, 588, 75-82.	1.0	0
2	The BRCA2 missense mutation K2497R suppressed self-degradation and increased ATP production and cell proliferation. Biochemical and Biophysical Research Communications, 2022, 590, 27-33.	1.0	0
3	Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors. Frontiers in Oncology, 2022, 12, 825284.	1.3	3
4	CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity. Biochemical and Biophysical Research Communications, 2021, 550, 56-61.	1.0	43
5	Integrative cancer genomics in the era of precision cancer medicine. Journal of Human Genetics, 2021, 66, 843-843.	1.1	0
6	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology, 2020, 22, 1064-1075.	4.6	182
7	Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. Npj Breast Cancer, 2020, 6, 25.	2.3	21
8	Estradiol/GPER affects the integrity of mammary duct-like structures in vitro. Scientific Reports, 2020, 10, 1386.	1.6	11
9	Crosstalk of DNA doubleâ€strand break repair pathways in poly(ADPâ€ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2â€mutated cancer. Cancer Science, 2018, 109, 893-899.	1.7	34
10	BRCA1 gene: function and deficiency. International Journal of Clinical Oncology, 2018, 23, 36-44.	1.0	83
11	Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nature Communications, 2018, 9, 4083.	5.8	179
12	FKBP51 regulates cell motility and invasion via RhoA signaling. Cancer Science, 2017, 108, 380-389.	1.7	15
13	Mutation status of RAD 51C , PALB 2 and BRIP 1 in 100 Japanese familial breast cancer cases without BRCA 1 and BRCA 2 mutations. Cancer Science, 2017, 108, 2287-2294.	1.7	13
14	<scp>LAMC</scp>2 is a predictive marker for the malignant progression of leukoplakia. Journal of Oral Pathology and Medicine, 2017, 46, 223-231.	1.4	30
15	Keratin 17 Is Induced in Oral Cancer and Facilitates Tumor Growth. PLoS ONE, 2016, 11, e0161163.	1.1	53
16	<scp>THBS</scp>1 is induced by <scp>TGFB</scp>1 in the cancer stroma and promotes invasion of oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2016, 45, 730-739.	1.4	90
17	BRCA2 mediates centrosome cohesion via an interaction with cytoplasmic dynein. Cell Cycle, 2016, 15, 2145-2156.	1.3	13
18	Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget, 2016, 7, 7701-7714.	0.8	35

#	Article	IF	Citations
19	BRCA2 Phosphorylated by PLK1 Moves to the Midbody to Regulate Cytokinesis Mediated by Nonmuscle Myosin IIC. Cancer Research, 2014, 74, 1518-1528.	0.4	35
20	Centrosomes at M phase act as a scaffold for the accumulation of intracellular ubiquitinated proteins. Cell Cycle, 2014, 13, 1928-1937.	1.3	8
21	Centrosomal BRCA2 is a target protein of membrane type-1 matrix metalloproteinase (MT1-MMP). Biochemical and Biophysical Research Communications, 2014, 443, 1148-1154.	1.0	12
22	Periostin suppression induces decorin secretion leading to reduced breast cancer cell motility and invasion. Scientific Reports, 2014, 4, 7069.	1.6	28
23	DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. Journal of Clinical Investigation, 2012, 122, 859-872.	3.9	114
24	Identification of Evi-1 as a novel effector of PKCÎ´ in the apoptotic response to DNA damage. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 285-294.	0.9	5
25	Identification of dihydropyrimidinaseâ€related protein 4 as a novel target of the p53 tumor suppressor in the apoptotic response to DNA damage. International Journal of Cancer, 2011, 128, 1524-1531.	2.3	30
26	BRCA2 and Nucleophosmin Coregulate Centrosome Amplification and Form a Complex with the Rho Effector Kinase ROCK2. Cancer Research, 2011, 71, 68-77.	0.4	51
27	Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer. Breast Cancer, 2010, 17, 97-102.	1.3	1
28	D4S234E, a novel p53-responsive gene, induces apoptosis in response to DNA damage. Experimental Cell Research, 2010, 316, 2849-2858.	1.2	17
29	The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Science, 2010, 101, 831-835.	1.7	99
30	ATM Augments Nuclear Stabilization of DYRK2 by Inhibiting MDM2 in the Apoptotic Response to DNA Damage. Journal of Biological Chemistry, 2010, 285, 4909-4919.	1.6	59
31	Roles of Interleukin-6 and Parathyroid Hormone-Related Peptide in Osteoclast Formation Associated with Oral Cancers. American Journal of Pathology, 2010, 176, 968-980.	1.9	71
32	Introduction and characterization of a polymeraseâ€dead point mutation into the POLK gene in vertebrates. FEBS Letters, 2009, 583, 661-664.	1.3	2
33	BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization. Cancer Science, 2009, 100, 2115-2125.	1.7	39
34	Molecular Prediction of Therapeutic Response and Adverse Effect of Chemotherapy in Breast Cancer. , 2009, , 177-182.		0
35	Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage. Cancer Science, 2008, 99, 747-754.	1.7	9
36	Identification of the Molecular Mechanisms for Dedifferentiation at the Invasion Front of Colorectal Cancer by a Gene Expression Analysis. Clinical Cancer Research, 2008, 14, 7215-7222.	3.2	29

#	Article	IF	Citations
37	A functional genome-wide RNAi screen identifies TAF1 as a regulator for apoptosis in response to genotoxic stress. Nucleic Acids Research, 2008, 36, 5250-5259.	6.5	39
38	BRCA1-Mediated Ubiquitination Inhibits Topoisomerase IIÎ±Activity in Response to Oxidative Stress. Antioxidants and Redox Signaling, 2008, 10, 939-950.	2.5	15
39	Interference with BRCA2, which localizes to the centrosome during S and early M phase, leads to abnormal nuclear division. Biochemical and Biophysical Research Communications, 2007, 355, 34-40.	1.0	47
40	DYRK2 Is Targeted to the Nucleus and Controls p53 via Ser46 Phosphorylation in the Apoptotic Response to DNA Damage. Molecular Cell, 2007, 25, 725-738.	4.5	258
41	Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. Cancer Science, 2007, 98, 740-746.	1.7	66
42	Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. Journal of Human Genetics, 2007, 52, 271-279.	1.1	32
43	JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nature Cell Biology, 2005, 7, 278-285.	4.6	228
44	Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science, 2004, 95, 866-871.	1.7	518
45	Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO Journal, 2003, 22, 1431-1441.	3.5	139